Ernexa Therapeutics (ERNAW) Total Non-Current Liabilities (2010 - 2026)

Ernexa Therapeutics has reported Total Non-Current Liabilities for 17 years, with the latest figure at $3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 66.2% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (down 66.2% YoY), and the FY2025 full-year result was $3.4 million, down 4.96% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $3.7 million, up from $3.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $55.0 million in Q2 2024, with the low at $2.5 million in Q3 2025.
• Historically, Total Non-Current Liabilities has averaged $21.7 million across 5 years, with a median of $9.8 million in 2022.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities jumped 619.3% — and 2025, when it slumped 95.31%.
• Ernexa Therapeutics' Total Non-Current Liabilities stood at $9.8 million in 2022, then jumped by 375.71% to $46.8 million in 2023, then slumped by 92.38% to $3.6 million in 2024, then slipped by 4.96% to $3.4 million in 2025, then increased by 8.64% to $3.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $3.7 million (Q1 2026), $3.4 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.